FDA "Leadership Role" In Halting WHO Ephedrine Scheduling Initiative Urged
This article was originally published in The Tan Sheet
Executive Summary
FDA should take a "leadership role to assure" the World Health Organization proposal to schedule ephedrine as a controlled substance under the 1971 Convention on Psychotropic Substances "does not go forward," the D.C. firm Hyman, Phelps & McNamara asserts in Feb. 10 comments to FDA.
You may also be interested in...
Ephedrine Psychotropic Drug Classification Unwarranted - WHO Committee
Ephedrine should not be classified as a psychotropic drug by the World Health Organization, according to a report drafted by the body's 32nd Expert Committee on Drug Dependence. The report was submitted at WHO meetings in Geneva, Switzerland Sept. 12-15.
Ephedrine Psychotropic Drug Classification Unwarranted - WHO Committee
Ephedrine should not be classified as a psychotropic drug by the World Health Organization, according to a report drafted by the body's 32nd Expert Committee on Drug Dependence. The report was submitted at WHO meetings in Geneva, Switzerland Sept. 12-15.
Ephedrine Psychotropic Drug Classification Unwarranted - WHO Committee
Ephedrine should not be classified as a psychotropic drug by the World Health Organization, according to a report drafted by the body's 32nd Expert Committee on Drug Dependence. The report was submitted at WHO meetings in Geneva, Switzerland Sept. 12-15.